TransMedics Group (NASDAQ:TMDX) Posts Quarterly Earnings Results, Beats Estimates By $0.21 EPS

TransMedics Group (NASDAQ:TMDX) issued its quarterly earnings data on Thursday. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.21, FiscalAI reports. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company had revenue of $203.01 million for the quarter, compared to the consensus estimate of $178.06 million. During the same quarter in the prior year, the firm earned $0.66 earnings per share. The firm’s revenue for the quarter was up 41.1% compared to the same quarter last year.

Here are the key takeaways from TransMedics Group’s conference call:

• TransMedics reported a record $203 million in third-quarter revenue, up 41% year over year, with liver and heart case volumes rising despite seasonal softness and a 6% decline in U.S. deceased-donor volume. The company raised 2026 revenue guidance to $764 million–$774 million, including about $14 million from PAD Aviation.
• Management highlighted upcoming growth opportunities in heart and lung: FDA approved protocol amendments for ENHANCE Heart Part B and DENOVO Lung, with enrollment expected to begin in early 2027. The company also remains on track for OCS Kidney’s first-in-human clinical experience in the second half of 2027, though these programs have not yet contributed meaningful revenue.
• TransMedics won its first European transplant-logistics tender, in Italy’s Emilia-Romagna region, and plans to launch OCS NOP in Italy, the Netherlands, and Belgium in the first half of 2027. Management sees additional tenders as a potential source of growth, but did not quantify the first award.
• Third-quarter GAAP gross margin was not specified, but reported gross margin was 58.5%, down 40 basis points year over year, partly because lower-margin service revenue and PAD Aviation made up a larger share of sales. Excluding PAD, gross margin improved to 61.1%; management expects some normalization in service margins in the fourth quarter and kept its full-year adjusted operating-margin outlook at 12.5%–14% amid planned investment.
• Executives acknowledged softer October flight trends and said fourth-quarter guidance assumes no meaningful revenue contribution from ENHANCE Part B or DENOVO, as well as potential holiday-season effects. They characterized the outlook as conservative and said recent flight data alone may not reflect total transport activity.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX traded down $3.77 during trading on Thursday, hitting $68.98. The company’s stock had a trading volume of 1,677,502 shares, compared to its average volume of 942,432. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The firm has a market cap of $2.38 billion, a price-to-earnings ratio of 17.73, a P/E/G ratio of 1.00 and a beta of 2.14. The company has a 50-day moving average of $79.68 and a 200-day moving average of $93.44. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. TD Cowen reiterated a “buy” rating and set a $120.00 target price on shares of TransMedics Group in a research note on Tuesday, September 8th. Barclays started coverage on TransMedics Group in a report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price target on the stock. Canaccord Genuity Group dropped their price target on TransMedics Group from $95.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, October 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Finally, Zacks Research raised TransMedics Group from a “strong sell” rating to a “hold” rating in a report on Monday. Five research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $115.60.

More TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Revenue rose 41.1% year over year to $203.0 million, above analyst expectations of about $178 million. Adjusted quarterly earnings were $0.51 per share, also ahead of estimates of $0.27–$0.30. TransMedics Q3 2026 results
• Positive Sentiment: TransMedics increased its full-year 2026 guidance, citing strong revenue generation, and pointed to near- and mid-term growth catalysts. TransMedics Q3 2026 results
• Negative Sentiment: Quarterly EPS was below the $0.66 reported a year earlier, which may have tempered the positive impact of the revenue growth and estimate beat. Earlier commentary also highlighted margin pressure and rising investment needs as risks. Reasons to retain TransMedics stock

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director David Weill bought 1,336 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was bought at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the transaction, the director owned 16,392 shares of the company’s stock, valued at $1,338,078.96. This represents a 8.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.90% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.